Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02NTS
|
||||
| Former ID |
DIB000312
|
||||
| Drug Name |
JNJ-39393406
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10:F01-F07, F04, F05, R41.3] | Phase 1 | [1] | ||
| Company |
Janssen Pharmaceutica NV
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H18F2N6O3
|
||||
| Canonical SMILES |
CN(C)C(=O)CCN1C(=NC(=N1)NC2=CC3=C(C=C2)OC(O3)(F)F)C4=CC<br />=NC=C4
|
||||
| InChI |
1S/C19H18F2N6O3/c1-26(2)16(28)7-10-27-17(12-5-8-22-9-6-12)24-18(25-27)23-13-3-4-14-15(11-13)30-19(20,21)29-14/h3-6,8-9,11H,7,10H2,1-2H3,(H,23,25)
|
||||
| InChIKey |
IURMHZBQEYNQOH-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Neuronal acetylcholine receptor protein, alpha-7 chain | Target Info | Modulator | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Nicotine addiction | |||||
| Chemical carcinogenesis | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Nicotinic acetylcholine receptor signaling pathway | |||||
| Reactome | Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01556217) A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers. U.S. National Institutes of Health. | ||||
| REF 2 | Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.